Items where authors include "Dodwell, D"

Export as [feed] Atom [feed] RSS
Number of items: 25.

Article

Bundred, N, Porta, N, Brunt, AM et al. (20 more authors) (2022) Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research. ISSN 1078-0432

Stevens, W, Farrow, IM, Georgiou, L et al. (9 more authors) (2021) Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response. The British Journal of Radiology. 20201396-. ISSN 0007-1285

Seligmann, JF, Wright-Hughes, A orcid.org/0000-0001-8839-6756, Pottinger, A et al. (10 more authors) (2020) Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. Clinical Oncology, 32 (10). pp. 656-664. ISSN 0936-6555

Gray, R, Bradley, R, Braybrooke, J et al. (164 more authors) (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet, 393 (10179). pp. 1440-1452. ISSN 0140-6736

Coleman, RE, Collinson, M orcid.org/0000-0003-3568-6455, Gregory, W orcid.org/0000-0003-2641-8416 et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13. pp. 123-135. ISSN 2212-1374

Wilson, C, Bell, R, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (5 more authors) (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94. pp. 70-78. ISSN 0959-8049

Asselain, B, Barlow, W, Bartlett, J et al. (107 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Alberro, JA, Ballester, B et al. (596 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Coleman, R, Hall, A, Albanell, J et al. (10 more authors) (2017) Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. The Lancet Oncology, 18 (11). pp. 1543-1552. ISSN 1470-2045

Wilson, C, Hinsley, S orcid.org/0000-0001-6903-4688, Marshall, H et al. (4 more authors) (2017) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – an AZURE (BIG 01/04) sub-study. Journal of Bone Oncology, 9. pp. 48-54. ISSN 2212-1374

Morden, JP, Alvarez, I, Bertelli, G et al. (18 more authors) (2017) Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 35 (22). pp. 2507-2514. ISSN 0732-183X

Wallington, M, Saxon, EB, Bomb, M et al. (11 more authors) (2016) 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncology, 17 (9). pp. 1203-1216. ISSN 1470-2045

Gahlaut, R, Bennett, A, Fatayer, H et al. (7 more authors) (2016) Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. European journal of cancer, 60. pp. 40-48. ISSN 0959-8049

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman, R, Powles, T et al. (102 more authors) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, 386 (10001). 1353 - 1361. ISSN 0140-6736

Coleman, R, Cameron, D, Dodwell, D et al. (13 more authors) (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15 (9). 997 - 1006. ISSN 1470-2045

Langlands, FE, Dodwell, D, Hanby, AM et al. (6 more authors) (2014) PSMD9 expression predicts radiotherapy response in breast cancer. Molecular Cancer, 13. 73. ISSN 1476-4598

Coleman, R, Hinsley, S orcid.org/0000-0001-6903-4688, Bell, R et al. (7 more authors) (2013) Adjuvant therapy in early breast cancer with zoledronic acid (AZURE - BIG 01/04): Final efficacy analysis. European Journal of Cancer, 49 (Suppl 3). S5-S5. ISSN 0959-8049

Pinhel, I, Hills, M, Drury, S et al. (27 more authors) (2012) ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Research, 14 (2). R46. ISSN 1465-5411

Coleman, RE, Marshall, H, Cameron, D et al. (7 more authors) (2011) Breast-cancer adjuvant therapy with zoledronic acid. The New England Journal of Medicine, 365 (15). 1396 - 1405. ISSN 0028-4793

Coleman, R, Woodward, E, Brown, J et al. (11 more authors) (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment, 127 (2). 429 - 438. ISSN 1573-7217

Coleman, RE, Winter, MC, Cameron, D et al. (11 more authors) (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer, 102 (7). 1099 - 1105. ISSN 0007-0920

Dodwell, D, Thorpe, H and Coleman, R (2009) Refining systemic therapy for early breast cancer: difficulties with subtraction. The Lancet Oncology, 10 (8). 738 - 739. ISSN 1470-2045

Humphreys, AC, Dent, J, Rodwell, S et al. (5 more authors) (2004) Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. British Journal of Cancer, 90 (11). pp. 2131-2134. ISSN 0007-0920

Conference or Workshop Item

Oughton, JB orcid.org/0000-0002-2047-804X, Wright-Hughes, A orcid.org/0000-0001-8839-6756 and Dodwell, D (2014) When the LANTERN goes out: feasibility studies in a changing clinical environment. In: Society for Clinical Trials 35th Annual Meeting, 18-21 May 2014, Philadelphia, Pennsylvania, USA.

Proceedings Paper

Battisti, NML, Wallington, M, Ring, A et al. (12 more authors) (2018) Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: A national registry study. In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Oxford University Press .

This list was generated on Sat Mar 23 14:17:20 2024 GMT.